vatalanib

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Brain and Central Nervous System Tumors

Conditions

Brain and Central Nervous System Tumors, Sarcoma

Trial Timeline

May 1, 2006 → Jul 1, 2013

NCT ID

NCT00348790

About vatalanib

vatalanib is a phase 2 stage product being developed by Novartis for Brain and Central Nervous System Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT00348790. Target conditions include Brain and Central Nervous System Tumors, Sarcoma.

What happened to similar drugs?

5 of 18 similar drugs in Brain and Central Nervous System Tumors were approved

Approved (5) Terminated (2) Active (13)

✅ExenatideAstraZenecaApproved

✅RivastigmineNovartisApproved

✅Genotropin (PN-180,307) SomatropinPfizerApproved

✅Genotropin + PlaceboPfizerApproved

✅Dotarem® + Gadovist®/Gadavist®GuerbetApproved

🔄Nivolumab + TemozolomideOno PharmaceuticalPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00348790	Phase 2	Completed	May 1, 2006	Jul 1, 2013	Brain and Central Nervous System Tumors
NCT00590343	Phase 2	Completed	Nov 1, 2004	Oct 1, 2010	Metastatic Neuroendocrine Tumors
NCT00056459	Phase 3	Completed	Feb 1, 2003	—	Colorectal Neoplasms
NCT00056446	Phase 3	Completed	Jan 1, 2003	Jan 1, 2007	Colorectal Neoplasms

Competing Products

20 competing products in Brain and Central Nervous System Tumors

See all competitors

Product	Company	Stage	Hype Score
Abemaciclib + Endocrine therapy	Eli Lilly	Phase 1/2	39
Duloxetine + Sugar pill	Eli Lilly	Phase 2	27
Neurosteroid enantiomer	Oragenics	Phase 2	32
Patritumab deruxtecan	Daiichi Sankyo	Phase 2	27
filgrastim + exatecan mesylate	Daiichi Sankyo	Phase 1	29
Eribulin Mesylate	Eisai	Phase 1	29
Pembrolizumab + Lenvatinib	Eisai	Phase 2	42
Palonosetron (Aloxi) and Dexamethasone	Eisai	Phase 2	27
GLIADEL	Eisai	Phase 2	35
Nivolumab + Temozolomide	Ono Pharmaceutical	Phase 3	40
Nivolumab + Temozolomide	Ono Pharmaceutical	Phase 3	40
Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastim	Eli Lilly	Phase 1	29
abemaciclib + abemaciclib	Eli Lilly	Phase 2	39
JNJ-17299425	Johnson & Johnson	Phase 2	27
ABT-888	AbbVie	Phase 1	29
Veliparib + Placebo	AbbVie	Phase 2	35
Iressa (Gefitinib)	AstraZeneca	Phase 2	27
Trastuzumab deruxtecan	AstraZeneca	Phase 2	42
Exenatide	AstraZeneca	Approved	43
AZD5213	AstraZeneca	Phase 1	29